Recent advances in understanding autoimmune thyroid disease: The tallest tree in the forest of polyautoimmunity

F1000Research

Volumn 6, Issue , 2017, Pages

  Bliddal, Sofie ^a   Nielsen, Claus Henrik ^a   Feldt Rasmussen, Ulla ^a  

^a University of Copenhagen   (Denmark)

Author keywords

AITD; Antibodies; Autoimmune disease; Graves' disease; Hashimoto's thyroiditis; Immunology; Polyautoimmunity; Thyroid autoimmunity

Indexed keywords

AUTOANTIBODY; IMMUNOMODULATING AGENT; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CLINICAL OUTCOME; CYTOKINE RELEASE; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; GENETIC VARIATION; HUMAN; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; NATURAL POLYAUTOIMMUNITY; NONHUMAN; POLYAUTOIMMUNE DISEASE; PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY T LYMPHOCYTE; REVIEW; RISK; SEX DIFFERENCE; SPONTANEOUS ABORTION; THYROID AUTOIMMUNITY;

EID: 85030665422     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.11535.1     Document Type: Review

References (109)

1. Weetman A DeGroot LJ: Autoimmunity to the Thyroid Gland.In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth (MA);2000. 25905407
2. Rojas-Villarraga A Amaya-Amaya J Rodriguez-Rodriguez A: Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis. 2012;2012: 254319. 22454759 10.1155/2012/254319 3290803
3. Ehrlich P: Verh Ges Dtsch Naturforsch.1902;1:250-275.
4. Welch WH: The Huxley Lecture on Recent Studies of Immunity, with Special Reference to their Bearing on Pathology: Delivered at the Opening of the Winter Session of Charing Cross Hospital Medical School on October 1st, 1902. Br Med J. 1902;2(2180):1105-14. 20760475 2401880
5. Metalnikoff S: Ann Inst Pasteur.1900;14:577-589.
6. Avrameas S Selmi C: Natural autoantibodies in the physiology and pathophysiology of the immune system. J Autoimmun. 2013;41:46-9. 23384670 10.1016/j.jaut.2013.01.006
7. Nakamura M Burastero SE Ueki Y: Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus. J Immunol. 1988;141(12):4165-72. 2848890
8. Berneman A Guilbert B Eschrich S: IgG auto- and polyreactivities of normal human sera. Mol Immunol. 1993;30(16):1499-510. 8232336
9. Nielsen CH Bendtzen K: Immunoregulation by naturally occurring and disease-associated autoantibodies: binding to cytokines and their role in regulation of T-cell responses. Adv Exp Med Biol. 2012;750:116-32. 22903670 10.1007/978-1-4614-3461-0_9
10. Nielsen CH Brix TH Gardas A: Epitope recognition patterns of thyroid peroxidase autoantibodies in healthy individuals and patients with Hashimoto's thyroiditis*. Clin Endocrinol (Oxf). 2008;69(4):664-8. 18363888 10.1111/j.1365-2265.2008.03245.x
11. Hayakawa K Asano M Shinton SA: Positive selection of natural autoreactive B cells. Science. 1999;285(5424):113-6. 10390361 10.1126/science.285.5424.113
12. Nossal GJ: Negative selection of lymphocytes. Cell. 1994;76(2):229-39. 8293461 10.1016/0092-8674(94)90331-X
13. Webb S Morris C Sprent J: Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell. 1990;63(6):1249-56. 2148123 10.1016/0092-8674(90)90420-J
14. Lutz HU Binder CJ Kaveri S: Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol. 2009;30(1):43-51. 19058756 10.1016/j.it.2008.10.002
15. Hurez V Dietrich G Kaveri SV: Polyreactivity is a property of natural and disease-associated human autoantibodies. Scand J Immunol. 1993;38(2):190-6. 8346418 10.1111/j.1365-3083.1993.tb01712.x
16. Rapoport B McLachlan SM: Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease. J Clin Endocrinol Metab. 2014;99(11):4060-1. 25210884 10.1210/jc.2014-3011 4223433
17. Figueroa-Vega N Alfonso-Pérez M Benedicto I: Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis. J Clin Endocrinol Metab. 2010;95(2):953-62. 20016049 10.1210/jc.2009-1719
18. Papp G Boros P Nakken B: Regulatory immune cells and functions in autoimmunity and transplantation immunology. Autoimmun Rev. 2017;16(5):435-44. 28286106 10.1016/j.autrev.2017.03.011 F1000 Recommendation
19. Ramos-Leví AM Marazuela M: Pathogenesis of thyroid autoimmune disease: the role of cellular mechanisms. Endocrinol Nutr. 2016;63(8):421-9. 27234136 10.1016/j.endonu.2016.04.003
20. Morris GP Brown NK Kong YM: Naturally-existing CD4(+)CD25(+)Foxp3(+) regulatory T cells are required for tolerance to experimental autoimmune thyroiditis induced by either exogenous or endogenous autoantigen. J Autoimmun. 2009;33(1):68-76. 19375891 10.1016/j.jaut.2009.03.010 2706097
21. González-Amaro R Marazuela M: T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity. Endocrine. 2016;52(1):30-8. 26475497 10.1007/s12020-015-0759-7 F1000 Recommendation
22. Roncarolo MG Gregori S Battaglia M: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28-50. 16903904 10.1111/j.0105-2896.2006.00420.x
23. von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005;6(4):338-44. 15785759 10.1038/ni1180
24. Bennett CL Christie J Ramsdell F: The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27(1):20-1. 11137993 10.1038/83713
25. Allan SE Passerini L Bacchetta R: The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest. 2005;115(11):3276-84. 16211090 10.1172/JCI24685 1242190
26. Kristensen B Hegedüs L Madsen HO: Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto's thyroiditis. Clin Exp Immunol. 2015;180(1):58-69. 25412700 10.1111/cei.12557 4367094
27. Yanaba K Bouaziz J Haas KM: A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28(5):639-50. 18482568 10.1016/j.immuni.2008.03.017
28. Weetman AP: The immunopathogenesis of chronic autoimmune thyroiditis one century after hashimoto. Eur Thyroid J. 2013;1(4):243-50. 24783026 10.1159/000343834 3821488 F1000 Recommendation
29. Brand O Gough S Heward J: HLA, CTLA-4 and PTPN22: The shared genetic master-key to autoimmunity? Expert Rev Mol Med. 2005;7(23):1-15. 16229750 10.1017/S1462399405009981
30. Mathis D Benoist C: Aire. Annu Rev Immunol. 2009;27:287-312. 19302042 10.1146/annurev.immunol.25.022106.141532
31. Caputo M Rivolta CM Mories T: Analysis of thyroglobulin gene polymorphisms in patients with autoimmune thyroiditis. Endocrine. 2010;37(3):389-95. 20960158 10.1007/s12020-010-9317-5
32. Zenewicz LA Abraham C Flavell RA: Unraveling the genetics of autoimmunity. Cell. 2010;140(6):791-7. 20303870 10.1016/j.cell.2010.03.003 3491807 F1000 Recommendation
33. Johar AS Mastronardi C Rojas-Villarraga A: Novel and rare functional genomic variants in multiple autoimmune syndrome and Sjögren's syndrome. J Transl Med. 2015;13:173. 26031516 10.1186/s12967-015-0525-x 4450850
34. Johar AS Anaya JM Andrews D: Candidate gene discovery in autoimmunity by using extreme phenotypes, next generation sequencing and whole exome capture. Autoimmun Rev. 2015;14(3):204-9. 25447288 10.1016/j.autrev.2014.10.021
35. Chu X Pan CM Zhao SX: A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet. 2011;43(9):897-901. 21841780 10.1038/ng.898
36. Lee HS Kang J Yang S: Susceptibility influence of a PTPN22 haplotype with thyroid autoimmunity in Koreans. Diabetes Metab Res Rev. 2011;27(8):878-82. 22069277 10.1002/dmrr.1265
37. Johar A Sarmiento-Monroy JC Rojas-Villarraga A: Definition of mutations in polyautoimmunity. J Autoimmun. 2016;72:65-72. 27209085 10.1016/j.jaut.2016.05.003 F1000 Recommendation
38. Chen JQ Papp G Szodoray P: The role of microRNAs in the pathogenesis of autoimmune diseases. Autoimmun Rev. 2016;15(12):1171-80. 27639156 10.1016/j.autrev.2016.09.003 F1000 Recommendation
39. Link M Salur L Kisand K: Higher FoxP3 mRNA expression in peripheral blood mononuclear cells of GAD65 or IA-2 autoantibody-positive compared with autoantibody-negative persons. APMIS. 2008;116(10):896-902. 19132983 10.1111/j.1600-0463.2008.00889.x
40. Ryder LR Bartels EM Woetmann A: FoxP3 mRNA splice forms in synovial CD4+ T cells in rheumatoid arthritis and psoriatic arthritis. APMIS. 2012;120(5):387-96. 22515293 10.1111/j.1600-0463.2011.02848.x
41. Catrina AI Svensson CI Malmström V: Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Rheumatol. 2017;13(2):79-86. 27974851 10.1038/nrrheum.2016.200 F1000 Recommendation
42. Lepez T Vandewoestyne M Deforce D: Fetal microchimeric cells in autoimmune thyroid diseases: harmful, beneficial or innocent for the thyroid gland? Chimerism. 2013;4(4):111-8. 23723083 10.4161/chim.25055 3921191
43. Stevens AM: Maternal microchimerism in health and disease. Best Pract Res Clin Obstet Gynaecol. 2016;31:121-30. 26612343 10.1016/j.bpobgyn.2015.08.005 F1000 Recommendation
44. Mynster Kronborg T Frohnert Hansen J Nielsen CH: Effects of the Commercial Flame Retardant Mixture DE-71 on Cytokine Production by Human Immune Cells. PLoS One. 2016;11(4):e0154621. 27128973 10.1371/journal.pone.0154621 4851365
45. Gleicher N Barad DH: Gender as risk factor for autoimmune diseases. J Autoimmun. 2007;28(1):1-6. 17261360 10.1016/j.jaut.2006.12.004
46. Brix TH Hegedüs L: Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (Oxf). 2012;76(4):457-64. 22168537 10.1111/j.1365-2265.2011.04318.x F1000 Recommendation
47. Bech K Bliddal H Feldt-Rasmussen U: Heterogeneity of autoimmune thyroiditis. Allergy. 1984;39(4):239-47. 6375440 10.1111/j.1398-9995.1984.tb00861.x
48. DeGroot LJ: Diagnosis and Treatment of Graves' Disease.In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth (MA);2000. 25905403
49. Vanderpump MP: The epidemiology of thyroid disease. Br Med Bull. 2011;99:39-51. 21893493 10.1093/bmb/ldr030
50. Pedersen IB Knudsen N Carlé A: A cautious iodization programme bringing iodine intake to a low recommended level is associated with an increase in the prevalence of thyroid autoantibodies in the population. Clin Endocrinol (Oxf). 2011;75(1):120-6. 21521277 10.1111/j.1365-2265.2011.04008.x F1000 Recommendation
51. Jørgensen KT Pedersen BV Nielsen NM: Childbirths and risk of female predominant and other autoimmune diseases in a population-based Danish cohort. J Autoimmun. 2012;38(2-3):J81-7. 21813263 10.1016/j.jaut.2011.06.004
52. Hansen PS Brix TH Iachine I: The relative importance of genetic and environmental effects for the early stages of thyroid autoimmunity: a study of healthy Danish twins. Eur J Endocrinol. 2006;154(1):29-38. 16381988 10.1530/eje.1.02060
53. Pedersen IB Knudsen N Jørgensen T: Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency. Clin Endocrinol (Oxf). 2003;58(1):36-42. 12519410 10.1046/j.1365-2265.2003.01633.x
54. Rasmussen AK Feldt-Rasmussen U Brandt M: Thyrotropin stimulates specifically the expression of the autoantibody binding domains of the thyroperoxidase molecule. Autoimmunity. 1999;29(4):323-31. 10433088 10.3109/08916939908994752
55. Smith TJ Hegedüs L: Graves' Disease. N Engl J Med. 2016;375:1552-65. 27797318 10.1056/NEJMra1510030 F1000 Recommendation
56. WITEBSKY E ROSE NR TERPLAN K: Chronic thyroiditis and autoimmunization. J Am Med Assoc. 1957;164(13):1439-47. 13448890 10.1001/jama.1957.02980130015004
57. Rose NR: Autoimmune diseases: tracing the shared threads. Hosp Pract (1995). 1997;32(4):147-54. 9109812 10.1080/21548331.1997.11443469
58. Sheehan NJ Stanton-King K: Polyautoimmunity in a young woman. Br J Rheumatol. 1993;32(3):254-6. 8448621 10.1093/rheumatology/32.3.254
59. Anaya JM Castiblanco J Rojas-Villarraga A: The multiple autoimmune syndromes. A clue for the autoimmune tautology. Clin Rev Allergy Immunol. 2012;43(3):256-64. 22648455 10.1007/s12016-012-8317-z
60. Humbert P Dupond JL: [Multiple autoimmune syndromes]. Ann Med Interne (Paris). 1988;139(3):159-68. 3059902
61. Eisenbarth GS Gottlieb PA: Autoimmune polyendocrine syndromes. N Engl J Med. 2004;350(20):2068-79. 15141045 10.1056/NEJMra030158
62. Halonen M Eskelin P Myhre AG: AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J Clin Endocrinol Metab. 2002;87(6):2568-74. 12050215 10.1210/jcem.87.6.8564
63. Myhre AG Undlien DE Løvås K: Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab. 2002;87(2):618-23. 11836294 10.1210/jcem.87.2.8192
64. Mackay IR: Clustering and commonalities among autoimmune diseases. J Autoimmun. 2009;33(3-4):170-7. 19837564 10.1016/j.jaut.2009.09.006
65. Zeher M Horvath IF Szanto A: Autoimmune thyroid diseases in a large group of Hungarian patients with primary Sjögren's syndrome. Thyroid. 2009;19(1):39-45. 19119981 10.1089/thy.2007.0398
66. Biró E Szekanecz Z Czirják L: Association of systemic and thyroid autoimmune diseases. Clin Rheumatol. 2006;25(2):240-5. 16247581 10.1007/s10067-005-1165-y
67. Nakamura H Usa T Motomura M: Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders. J Endocrinol Invest. 2008;31(10):861-5. 19092289 10.1007/BF03346432 F1000 Recommendation
68. Liao KP Kurreeman F Li G: Associations of autoantibodies, autoimmune risk alleles, and clinical diagnoses from the electronic medical records in rheumatoid arthritis cases and non-rheumatoid arthritis controls. Arthritis Rheum. 2013;65(3):571-81. 23233247 10.1002/art.37801 3582761
69. Feldt-Rasmussen U Høier-Madsen M Bech K: Anti-thyroid peroxidase antibodies in thyroid disorders and non-thyroid autoimmune diseases. Autoimmunity. 1991;9(3):245-54. 1777557 10.3109/08916939109007650
70. Fallahi P Ferrari SM Ruffilli I: The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients. Autoimmun Rev. 2016;15(12):1125-8. 27639841 10.1016/j.autrev.2016.09.009 F1000 Recommendation
71. Di Mario U Perfetti R Anastasi E: Autoantibodies to insulin do appear in non-diabetic patients with autoimmune disorders: comparison with anti-immunoglobulin antibodies and other autoimmune phenomena. Acta Endocrinol (Copenh). 1990;122(3):303-8. 2183533 10.1530/acta.0.1220303
72. Boelaert K Newby PR Simmonds MJ: Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123(2):183.e1-9. 20103030 10.1016/j.amjmed.2009.06.030 F1000 Recommendation
73. Wiebolt J Achterbergh R den Boer A: Clustering of additional autoimmunity behaves differently in Hashimoto's patients compared with Graves' patients. Eur J Endocrinol. 2011;164(5):789-94. 21378091 10.1530/EJE-10-1172
74. Eaton WW Pedersen MG Atladóttir HO: The prevalence of 30 ICD-10 autoimmune diseases in Denmark. Immunol Res. 2010;47(1-3):228-31. 20066507 10.1007/s12026-009-8153-2 2892249
75. Eaton WW Rose NR Kalaydjian A: Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007;29(1):1-9. 17582741 10.1016/j.jaut.2007.05.002 2717015
76. Somers EC Thomas SL Smeeth L: Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? Am J Epidemiol. 2009;169(6):749-55. 19224981 10.1093/aje/kwn408
77. Ottesen M Feldt-Rasmussen U Andersen J: Thyroid function and autoimmunity in pernicious anemia before and during cyanocobalamin treatment. J Endocrinol Invest. 1995;18(2):91-7. 7629393 10.1007/BF03349707
78. Anaya JM: The diagnosis and clinical significance of polyautoimmunity. Autoimmun Rev. 2014;13(4-5):423-6. 24424171 10.1016/j.autrev.2014.01.049
79. Raterman HG Voskuyl AE Simsek S: Increased progression of carotid intima media thickness in thyroid peroxidase antibodies-positive rheumatoid arthritis patients. Eur J Endocrinol. 2013;169(6):751-7. 24005313 10.1530/EJE-13-0394
80. Willeit P Thompson SG Agewall S: Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. Eur J Prev Cardiol. 2016;23(2):194-205. 25416041 10.1177/2047487314560664 4544641
81. Caforio AL Wagner R Gill JS: Organ-specific cardiac antibodies: serological markers for systemic hypertension in autoimmune polyendocrinopathy. Lancet. 1991;337(8750):1111-5. 1674011 10.1016/0140-6736(91)92784-Y
82. de Jesus GR Agmon-Levin N Andrade CA: 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev. 2014;13(8):795-813. 24650941 10.1016/j.autrev.2014.02.003
83. Chen LM Zhang Q Si GX: Associations between thyroid autoantibody status and abnormal pregnancy outcomes in euthyroid women. Endocrine. 2015;48(3):924-8. 25209893 10.1007/s12020-014-0420-x
84. Thangaratinam S Tan A Knox E: Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ. 2011;342:d2616. 21558126 10.1136/bmj.d2616 3089879 F1000 Recommendation
85. Iijima T Tada H Hidaka Y: Effects of autoantibodies on the course of pregnancy and fetal growth. Obstet Gynecol. 1997;90(3):364-9. 9277645 10.1016/S0029-7844(97)00283-4 F1000 Recommendation
86. Mekinian A Cohen J Alijotas-Reig J: Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation? Am J Reprod Immunol. 2016;76(1):8-28. 26847715 10.1111/aji.12493 F1000 Recommendation
87. Piga M Serra A Deiana L: Brain perfusion abnormalities in patients with euthyroid autoimmune thyroiditis. Eur J Nucl Med Mol Imaging. 2004;31(12):1639-44. 15290119 10.1007/s00259-004-1625-7
88. Montagna G Imperiali M Agazzi P: Hashimoto's encephalopathy: A rare proteiform disorder. Autoimmun Rev. 2016;15(5):466-76. 26849953 10.1016/j.autrev.2016.01.014
89. Watt T Hegedüs L Bjorner JB: Is Thyroid Autoimmunity per se a Determinant of Quality of Life in Patients with Autoimmune Hypothyroidism? Eur Thyroid J. 2012;1(3):186-92. 24783018 10.1159/000342623 3821477
90. Bové KB Watt T Vogel A: Anxiety and depression are more prevalent in patients with graves' disease than in patients with nodular goitre. Eur Thyroid J. 2014;3(3):173-8. 25538899 10.1159/000365211 4224229
91. Avouac J Airò P Dieude P: Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European Caucasian patients. J Rheumatol. 2010;37(3):608-14. 20110522 10.3899/jrheum.090815
92. Marinó M Ricciardi R Pinchera A: Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab. 1997;82(2):438-43. 9024233 10.1210/jcem.82.2.3749
93. Wiersinga WM Duntas L Fadeyev V: 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism. Eur Thyroid J. 2012;1(2):55-71. 24782999 10.1159/000339444 3821467
94. Coles AJ Wing M Smith S: Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354(9191):1691-5. 10568572 10.1016/S0140-6736(99)02429-0
95. Mandac JC Chaudhry S Sherman KE: The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43(4):661-72. 16557537 10.1002/hep.21146
96. Antonelli A Ferri C Fallahi P: Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol. 2009;6(11):633-5. 19881515 10.1038/nrgastro.2009.168
97. Stefan M Jacobson EM Huber AK: Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J Biol Chem. 2011;286(36):31168-79. 21757724 10.1074/jbc.M111.247510 3173071
98. Spain L Diem S Larkin J: Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60. 26874776 10.1016/j.ctrv.2016.02.001 F1000 Recommendation
99. Corsello SM Barnabei A Marchetti P: Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361-75. 23471977 10.1210/jc.2012-4075
100. Bliddal S Borresen SW Feldt-Rasmussen U: Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis. Front Endocrinol (Lausanne). 2017;8:179. 28824542 10.3389/fendo.2017.00179 5534470
101. Raterman HG Jamnitski A Lems WF: Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study. J Rheumatol. 2011;38(2):247-51. 21078720 10.3899/jrheum.100488
102. El Fassi D Nielsen CH Hasselbalch HC: Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid. 2006;16(7):709-10. 16889501 10.1089/thy.2006.16.709
103. Nielsen CH El Fassi D Hasselbalch HC: B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family. Expert Opin Biol Ther. 2007;7(7):1061-78. 17665994 10.1517/14712598.7.7.1061
104. Salvi M Vannucchi G Currò N: Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422-31. 25494967 10.1210/jc.2014-3014 4318899 F1000 Recommendation
105. Buch MH Smolen JS Betteridge N: Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-20. 21378402 10.1136/ard.2010.144998 3086093
106. Hauser SL Waubant E Arnold DL: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-88. 18272891 10.1056/NEJMoa0706383 F1000 Recommendation
107. Pescovitz MD Greenbaum CJ Krause-Steinrauf H: Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143-52. 19940299 10.1056/NEJMoa0904452 F1000 Recommendation
108. Smith TJ Kahaly GJ Ezra DG: Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017;376(18):1748-61. 28467880 10.1056/NEJMoa1614949 F1000 Recommendation
109. Baker KF Isaacs JD: Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2017; pii: annrheumdis-2017-211555. 28765121 10.1136/annrheumdis-2017-211555 F1000 Recommendation